Pfizer makes moves to acquire Seagen in potential $30B+ deal
Pfizer is in talks to acquire cancer drugmaker Seagen in a deal that could be worth more than $30 billion, after acquisition talks between Merck and the biotech broke down last year, the Wall Street Journal reported Sunday night.
A potential deal between Pfizer and Seagen isn’t a guarantee and the talks are still at an early stage, the WSJ reported, citing people familiar with the matter. Representatives for Seagen and Pfizer declined to comment.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters